CrisprBits, a Bengaluru-based biotechnology startup, has raised $3 million in its pre-Series A funding round led by Spectrum Impact, the family office of Rajendra Gogri, Chairman and Managing Director of Aarti Industries.
The round also saw participation from the founders and existing investors, including Vijay Alreja Family Office (VJ Technologies Group) and new investors, including the promoter family of HBL Engineering.
The round brings the company’s valuation to $12 million. Earlier, CrisprBits had raised $250,000 in pre-seed funding from the founders, VJ Technologies Group and C-CAMP (Centre for Cellular and Molecular Platforms).
The fresh funds raised will be used to scale commercialization of the PathCrisp molecular diagnostics platform, augmenting manufacturing capacity for high-impact tests in human health (e.g., Sickle Cell, Typhoid and Anti-Microbial Resistance), food safety, and animal health. The fund will also accelerate the development of a cutting-edge, CRISPR-driven strain engineering platform, starting with the optimization of processes for biofuel production to address unmet industrial sustainability needs.
Founded in 2020 by Vijay Chandru, Sunil Arora, Prof. Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda, CrisprBits is a biotechnology company that is developing high-quality and affordable solutions in CRISPR-based diagnostics and gene editing.
Its platforms accelerate detection of drug-resistant infections, enable low-cost genome engineering, and power personalized treatments for rare genetic diseases. CrisprBits technology can be deployed in hospitals, farms, and industries, ensuring timely health interventions, safer food, sustainable agriculture, and climate resilience.
Over the next six months, CrisprBits plans to expand its CRISPR-based diagnostic products into global markets, including Africa and Latin America. The company also plans to strengthen its operations by expanding infrastructure and production capabilities at its diagnostics manufacturing facility. Additionally, the company plans to build a proprietary AI-augmented strain engineering platform for sustainability solutions, including enhancing biofuel production.
Vijay Chandru, CEO, CrisprBits, said, “Our focus has always been on attracting patient capital that shares our visionary goal: to Rewrite Biology and Reimagine the Planet. This funding round provides the fuel for that mission and our team of pioneering CRISPR scientists and results-driven commercial leadership. We are now perfectly positioned to not just launch our products and services in India, but to immediately scale to global markets, ensuring our innovation delivers high-quality, affordable solutions at a truly international scale.”
Mirik Gogri, Principal at Spectrum Impact Family Office, said, “Our family office is excited to invest in CrisprBits. Given our experience in the process industry, we see a clear opportunity for synthetic biology to unlock new industrial frontiers. CrisprBits’ strategy is perfectly poised to deliver multidimensional impact: high-quality diagnostics hitting the market very soon, and the pioneering strain engineering that will enable a more cost-effective future for biochemicals and biofuels. CrisprBits is taking a powerful technology and turning it into immense commercial and societal value. We look forward to working closely with them through this partnership.”
